News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>BOCOMI Lifts CSPC PHARMA (01093.HK) TP to $7.2, Keeps Rating at Neutral
CSPC PHARMA (01093.HK) continued to face pressure in its 1Q25 results, with revenue excluding BD income falling by 30% YoY, BOCOMI released a research report saying. Of which, the ...
Reset
Send
The window will close in 5 seconds
<Research>BOCOMI Lifts CSPC PHARMA (01093.HK) TP to $7.2, Keeps Rating at Neutral
Close
Recommend
3
Positive
7
Negative
3
 
SHORT SELL
 
STOCK INFO

CSPC PHARMA (01093.HK)  +0.410 (+4.649%)    Short selling $688.76M; Ratio 25.391%   continued to face pressure in its 1Q25 results, with revenue excluding BD income falling by 30% YoY, BOCOMI released a research report saying.

Of which, the OTC drug business declined by 37%, while sales of anti-tumor products dropped by 66%, with a fall of nearly 30% in the CNS segment. However, the Company is expected to achieve three major overseas licensing deals this year, each potentially involving over US$5 billion.

Related NewsHSBC Research Upgrades CSPC PHARMA to Buy, Raises TP to HKD9.5
Coupled with enhanced promotion of NBP, the inclusion of Duomeisu in centralized procurement and less impact from channel inventory de-stocking in the Company, the broker anticipated CSPC PHARMA to recognize more BD income in the future, and lifted its target price from $5.8 to $7.2, with rating kept at Neutral.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-09 16:25.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.